SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Discussion centers on reports that Nvidias board may remove Jensen Huang, alongside widespread but unverified claims that he has resigned amid affair allegations and scrutiny over possible China-related compliance issues. Traders debate the leadership and governance risk, with some fearing damage to Nvidias AI business and others arguing its fundamentals remain intact and treating the selloff as a buying opportunity.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius strong quarterly results are being overshadowed by a softer near-term outlook, delayed capacity ramp, and sharply higher capital spending, which traders fear could pressure funding and lead to dilution. Bulls point to robust AI-cloud demand and customer prepayments, while bears focus on execution and the cost of expansion.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondass quarterly results and higher revenue outlook are driving attention, with traders highlighting stronger sales, a larger backlog and an earlier profitability timeline. The reaction is split: bullish traders see accelerating defense-business growth and potential short covering, while skeptics point to margin pressure, widening operating losses, cash burn and dilution concerns.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines quarterly results beat expectations, with traders highlighting positive free cash flow and a record backlog; the NASA CLPS 2 selection is also part of the bullish backdrop. Bulls see evidence of improving execution, while skeptics point to ongoing losses, dilution and the need to convert backlog into billings.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors rally is driven by anticipation of the FDA decision on deramiocel for Duchenne muscular dystrophy, with the application focused on preserving upper-limb function; managements confidence and analyst upgrades have added to optimism. Traders are debating the binary outcomesome expect approval and a squeeze, while others point to the earlier advisory-panel vote and continued regulatory uncertainty.

Figure Technology Solutions, Inc. is a blockchain-native capital marketplace, which engages in connecting origination, funding, and secondary market activity. It operates through the following segments: FTI, Markets, and Other. The FTI segment offers Figure Connect which generates ecosystem and technology fees, and originates, sells, and securitizes home equity line of credit (HELOC) loans that it services. The Markets segment utilizes blockchain technology to develop an exchange for digital assets and credit, with new product offerings including providing interest-bearing stable coin deposits. The company was founded by Michael Scott Cagney and June Ou in 2018 and is headquartered in Reno, NV.

Figure Technology Solutions Inc. - Ordinary Shares - Class A

Figure Technology Solutions Inc

Figures Q3 earnings beat revenue and EPS expectations, and traders also highlighted an increased share-buyback authorization. The reaction is broadly bullish on the results and operating leverage, though some traders were disappointed by the lack of stronger guidance and remain focused on take-rate concerns and volatile, short-heavy trading.

Boost Run, Inc. is a provider of scalable cloud infrastructure purpose-built for enterprise AI and high-performance computing workloads. The platform delivers GPU compute, CPU nodes, managed Kubernetes orchestration, and shared storage through an intuitive management console and a robust API layer, enabling organizations to provision and scale resources across thousands of nodes in minutes. The company was founded on September 5, 2025 and is headquartered in Northbrook, IL.

Boost Run Inc. - Ordinary Shares - Class A

Boost Run Inc.

BRUN is drawing attention around its Q3 results: revenue grew sharply year over year but missed expectations, prompting traders to question whether its large contracted backlog can translate into sustained revenue and profitability. Bulls point to contract growth and financing progress, while skeptics focus on the miss and execution risks.

ERock, Inc. operates, designs, and installs distributed generation power systems. The firm primarily serves data centers, utilities, commercial and industrial businesses. The company was founded on 2006 and is headquartered in Houston, TX.

ERock Inc. - Ordinary Shares - Class A

ERocks Q3 results are drawing attention, with traders highlighting a return to profitability, strong revenue growth, an expanded backlog, and reaffirmed full-year guidance. Many see the results as validation of its natural-gas microgrid role in powering AI data centers, while others remain wary of volatility, short interest, and execution risks.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

A hotter-than-expected CPI print has lifted Treasury yields and the dollar, while traders price in a more hawkish Fed outlook, pressuring gold and GLD. The selloff has prompted bearish calls for further declines, though some investors are buying the dip and looking for a rebound.

Cardinal Infrastructure Group, Inc. provides infrastructure services to the residential, commercial, industrial, municipal, and state infrastructure markets. It delivers wet utility installations of water, sewer, and stormwater systems, as well as grading, site clearing, erosion control, drilling and blasting, paving, and other related site services. The company was founded on June 12, 2025 and is headquartered in Raleigh, NC.

Cardinal Infrastructure Group Inc - Ordinary Shares - Class A

Cardinals Q3 miss and withdrawal of its 2026 revenue and margin guidance, amid a sharp margin squeeze, are driving the selloff and discussion. Traders are split between calling the shares oversold and focusing on management credibility, the postponed Hughes Brothers deal, and whether the buyback can restore confidence.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade

The consensus price target hints at a 124.6% upside potential for Vor Biopharma (VOR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Jefferies Financial Group Upgrades Vor Biopharma (NASDAQ:VOR) to Strong-Buy

Jefferies Financial Group upgraded shares of Vor Biopharma to a "strong-buy" rating in a report on Thursday...

Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from Brokerages

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the thirteen analysts that are presently covering the stock, Marketbeat reports. One...

Vor Biopharma Inc. (NASDAQ:VOR) Short Interest Down 17.3% in April

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) was the target of a significant drop in short interest in the month of April. As of April 15th, there was short interest totaling 4,706,707 shares, a...

Vor Biopharma (NASDAQ:VOR) Director Ra Capital Management, L.P. Sells 165,150 Shares

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) Director Ra Capital Management, L.P. sold 165,150 shares of the business's stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $15.77, for a total value of $2,604,415.50. Following the sale, the director...

Vor Biopharma (NASDAQ:VOR) Director Sells $2,711,856.51 in Stock

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) Director Ra Capital Management, L.P. sold 171,963 shares of the stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $15.77, for a total transaction of $2,711,856.51. Following the sale, the...

Vor Biopharma (NASDAQ:VOR) Director Sells $7,462,931.08 in Stock

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) Director Ra Capital Management, L.P. sold 458,411 shares of the firm's stock in a transaction that occurred on Friday, April 17th. The shares were...

Insider Selling: Vor Biopharma (NASDAQ:VOR) Director Sells 171,963 Shares of Stock

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) Director Ra Capital Management, L.P. sold 171,963 shares of the company's stock in a transaction dated Monday, April 20th. The stock was sold at an...

Vor Biopharma (NASDAQ:VOR) Shares Down 4.4% - Here's What Happened

Vor Biopharma (NASDAQ:VOR) Shares Down 4.4% - Here's What Happened...

Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 117% in Vor Biopharma (VOR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Vor Biopharma, Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. It is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Boston, MA.

Vor Biopharma Inc

VOR Shares Rally Over 40% In Pre-Market Trade After JPMorgan Initiates Bullish Coverage 

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Vor Biopharma shares surged over&nbsp;40%&nbsp;after JPMorgan initiated coverage of the company.&nbsp;</li><li>JPMorgan’s bullish stance comes amid Phase 3 clinical trial success for an autoimmune drug, telitacicept.&nbsp;</li><li>On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ while message volume rose to ‘extremely high’ levels.</li></ul>Shares of Vor Biopharma Inc. (VOR) rallied over 40% on Tuesday in premarket trading after JPMorgan initiated coverage of the clinical-stage biopharma company with a bullish stance.&nbsp;In a note on Tuesday, as cited by TheFly, JPMorgan awarded&nbsp;<a href="https://stocktwits.com/symbol/VOR">VOR</a> with an ‘Overweight’ rating and set a price target of $43. The firm said that it views VOR’s telitacicept, a recombinant fusion protein that is intended to treat autoimmune diseases, as "highly de-risked" across a range of indications.&nbsp;<h2 class="st-heading-2">Tapping Market Gaps</h2>JPMorgan’s coverage comes amid the pharma company’s success in its autoimmune disease treatment plans. In its latest quarterly results, VOR noted that telitacicept has “demonstrated consistent results on multiple efficacy endpoints, durable benefit, and a favorable safety profile”.&nbsp;VOR has a "significant valuation disconnect", JPMorgan said in its note, highlighting the probability-adjusted value of telitacicept to treat chronic conditions of myasthenia gravis and primary Sjogren's disease alone. The firm added that VOR, while focused on global indications that are less competitive, still has an unmet need that is significant.&nbsp;In other news, Vor Biopharma&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.vorbio.com/news-releases/news-release-details/vor-bio-announces-pricing-public-offering-100-million-common">announced</a> a $100 million public offering of common stock priced at $10 per share in November.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around VOR jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1286/155;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_09_at_6_11_06_PM_png_fd2a6ad6c4.webp" alt="On Stocktwits, retail sentiment around VOR jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels." width="1286" height="155"></figure>One user on the platform predicted that VOR’s share price could go up to $20. The stock was trading around $10 at the time of writing.&nbsp;<a href="https://stocktwits.com/apux/message/638580684">https://stocktwits.com/apux/message/638580684</a>Shares of VOR have fallen almost 60% in the past one year.For updates and corrections, email newsroom[at]stocktwits[dot]com&nbsp;

Young female scientist working in laboratory (Representative image courtesy of Solskin via Getty Images)

The firm gave Vor Biopharma an ‘Overweight’ rating with a price target of $43. 

VOR Shares Rally Over 40%In Pre-Market Trade After JPMorgan Initiates Bullish Coverage 

The firm gave Vor Biopharma an ‘Overweight’ rating with a price target of $43. 


Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	-$0.99	--	--	N/A
Q3 '26	-$1.14	-$1.45	-27.28%	MISSED
Q2 '26	-$0.96	-$1.16	-21.20%	MISSED
Q1 '26	-$4.99	--	--	N/A
Q4 '25	$22.43	--	--	N/A

Feed

News

Sentiment

Earnings

Fundamentals

Info

VOR Earnings

Latest Earnings Results: Q3 '26

Historical Earnings